- Latest available (Revised)
- Point in Time (23/09/2013)
- Original (As adopted by EU)
Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
Version Superseded: 31/12/2020
Point in time view as at 23/09/2013.
There are currently no known outstanding effects by UK legislation for Regulation (EU) No 528/2012 of the European Parliament and of the Council, ANNEX II.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
With regard to the ADS, the data elements to be provided for a specific active substance shall be determined by considering each of the ADS data elements indicated in this Annex taking into account, inter alia, the physical and chemical properties of the substance, existing data, information which is part of the CDS and the types of products in which the active substance will be used and the exposure patterns related to these uses.
Specific indications for the inclusion of some data elements are provided in column 1 of the Annex II table. The general considerations regarding adaptation of information requirements as set out in Annex IV shall also apply. In light of the importance of reducing testing on vertebrates, column 3 of the Annex II table gives specific indications for the adaptation of some of the data elements which might require the use of such tests on vertebrates. The information submitted shall, in any case, be sufficient to support a risk assessment demonstrating that the criteria referred to in Article 4(1) are met.
The applicant should consult the detailed technical guidance regarding the application of this Annex and the preparation of the dossier referred to in point (a) of Article 6(1), which is available on the website of the Agency.
The applicant has the obligation to initiate a pre-submission consultation. In addition to the obligation set down in Article 62(2), applicants may also consult with the competent authority that will evaluate the dossier with regard to the proposed information requirements and in particular the testing on vertebrates that the applicant proposes to carry out.
Additional information may need to be submitted if it is necessary to carry out the evaluation as indicated in Article 8(2).
Information required to support the approval of an active substance is listed in the table below.
Conditions for not requiring a specific test that are set out in the appropriate test methods in the Regulation (EC) No 440/2008 and are not repeated in column 3, also apply.
a The information provided should be for the purified active substance of stated specification or for the active substance as manufactured, if different. | ||
b The information provided should be for the purified active substance of stated specification. | ||
Column 1Information required | Column 2All data is CDS unless indicated as ADS | Column 3Specific rules for adaptation from standard information concerning some of the information requirements that may require recourse to testing of vertebrates |
---|---|---|
1. APPLICANT | ||
1.1.Name and address | ||
1.2.Contact person | ||
1.3.Active substance manufacturer (name, address and location of manufacturing plant(s)) | ||
2. IDENTITY OF THE ACTIVE SUBSTANCE | ||
For the active substance, the information given in this Section shall be sufficient to enable the active substance to be identified. If it is not technically possible or if it does not appear scientifically necessary to give information on one or more of the items below, the reasons shall be clearly stated | ||
2.1.Common name proposed or accepted by ISO and synonyms (usual name, trade name, abbreviation) | ||
2.2.Chemical name (IUPAC and CA nomenclature or other international chemical name(s)) | ||
2.3.Manufacturer’s development code number(s) | ||
2.4.CAS number plus EC, INDEX and CIPAC numbers | ||
2.5.Molecular and structural formula (including SMILES notation, if available and appropriate) | ||
2.6.Information on optical activity and full details of any isomeric composition (if applicable and appropriate) | ||
2.7.Molar mass | ||
2.8.Method of manufacture (syntheses pathway) of active substance including information on starting materials and solvents including suppliers, specifications and commercial availability | ||
2.9.Specification of purity of the active substance as manufactured in g/kg, g/l or %w/w (v/v) as appropriate, providing inclusively the upper and lower limit | ||
2.10.The identity of any impurities and additives including by-products of synthesis, optical isomers, degradation products (if the substance is unstable) un-reacted and end-groups etc. of polymers and un-reacted starting materials of UVC-substances | ||
2.11.Analytical profile of at least five representative batches (g/kg active substance) including information on content of the impurities referred to in 2.10. | ||
2.12.The origin of the natural active substance or the precursor(s) of the active substance, e.g. an extract of a flower | ||
3. PHYSICAL AND CHEMICAL PROPERTIES OF THE ACTIVE SUBSTANCE | ||
3.1. Appearancea | ||
3.1.1.Aggregate state (at 20 °C and 101,3 kPa) | ||
3.1.2.Physical state (i.e. viscous, crystalline, powder) (at 20 °C and 101,3 kPa) | ||
3.1.3.Colour (at 20 °C and 101,3 kPa) | ||
3.1.4.Odour (at 20 °C and 101,3 kPa) | ||
3.2.Melting/freezing pointb | ||
3.3.Acidity, alkalinity | ||
3.4.Boiling pointb | ||
3.5.Relative Densityb | ||
3.6.Absorption spectra data (UV/VIS, IR, NMR) and a mass spectrum, molar extinction coefficient at relevant wavelengths, where relevantb | ||
3.7. Vapour pressureb | ||
3.7.1.Henry’s law constant must always be stated for solids and liquids if it can be calculated | ||
3.8.Surface tensionb | ||
3.9.Water solubilityb | ||
3.10.Partition coefficient (n-octanol/water) and its pH dependencyb | ||
3.11.Thermal stability, identity of breakdown productsb | ||
3.12.Reactivity towards container material | ||
3.13.Dissociation constant | ADS | |
3.14.Granulometry | ||
3.15.Viscosity | ADS | |
3.16.Solubility in organic solvents, including effect of temperature on solubilityb | ADS | |
3.17.Stability in organic solvents used in biocidal products and identity of relevant breakdown productsa | ADS | |
4. PHYSICAL HAZARDS AND RESPECTIVE CHARACTERISTICS | ||
4.1.Explosives | ||
4.2.Flammable gases | ||
4.3.Flammable aerosols | ||
4.4.Oxidising gases | ||
4.5.Gases under pressure | ||
4.6.Flammable liquids | ||
4.7.Flammable solids | ||
4.8.Self-reactive substances and mixtures | ||
4.9.Pyrophoric liquids | ||
4.10.Pyrophoric solids | ||
4.11.Self-heating substances and mixtures | ||
4.12.Substances and mixtures which in contact with water emit flammable gases | ||
4.13.Oxidising liquids | ||
4.14.Oxidising solids | ||
4.15.Organic peroxides | ||
4.16.Corrosive to metals | ||
4.17. Additional physical indicators for hazards | ||
4.17.1.Auto-ignition temperature (liquids and gases) | ||
4.17.2.Relative self ignition temperature for solids | ||
4.17.3.Dust explosion hazard | ||
5. METHODS OF DETECTION AND IDENTIFICATION | ||
5.1.Analytical methods including validation parameters for the determination of active substance as manufactured and where appropriate, for relevant residues, isomers and impurities of the active substance and additives (e.g. stabilisers)For impurities other than relevant impurities this only applies if they are present at ≥ 1 g/kg | ||
5.2. Analytical methods for monitoring purposes including recovery rates and the limits of quantification and detection for the active substance, and for residues thereof in/on the following where relevant | ||
5.2.1.Soil | ||
5.2.2.Air | ||
5.2.3.Water (surface, drinking etc.) and sediment | ||
5.2.4.Animal and human body fluids and tissues | ||
5.3.Analytical methods for monitoring purposes including recovery rates and the limit of quantification and detection for the active substance, and for residues thereof, in/on food of plant and animal origin or feeding stuffs and otherproducts where relevant (not necessary if neither the active substance nor articles treated with it come into contact with food-producing animals, food of plant or animal origin or feeding stuffs) | ADS | |
6. EFFECTIVENESS AGAINST TARGET ORGANISMS | ||
6.1.Function, e.g. fungicide, rodenticide, insecticide, bactericide and mode of control e.g. attracting, killing, inhibiting | ||
6.2.Representative organism(s) to be controlled and products, organisms or objects to be protected | ||
6.3.Effects on representative target organism(s) | ||
6.4.Likely concentration at which the active substance will be used in products and, where appropriate, in treated articles | ||
6.5.Mode of action (including time delay) | ||
6.6.Efficacy data to support these claims on biocidal products and, where label claims are made, on treated articles, including any available standard protocols, laboratory tests or field trials used including performance standards where appropriate | ||
6.7. Any known limitations on efficacy | ||
6.7.1.Information on the occurrence or possible occurrence of the development of resistance and appropriate management strategies | ||
6.7.2.Observations on undesirable or unintended side-effects, e.g. on beneficial and other non-target organisms | ||
7. INTENDED USES AND EXPOSURE | ||
7.1.Field of use(s) envisaged for biocidal products and, where appropriate, treated articles | ||
7.2.Product-type(s) | ||
7.3.Detailed description of the intended use pattern(s) including in treated articles | ||
7.4.Users e.g. industrial, trained professional, professional or general public (non-professional) | ||
7.5.Likely tonnage to be placed on the market per year and, where relevant, for the envisaged major use categories | ||
7.6. Exposure data in conformity with Annex VI to this Regulation | ||
7.6.1.Information on human exposure associated with the intended uses and disposal of the active substance | ||
7.6.2.Information on environmental exposure associated with the intended uses and disposal of the active substance | ||
7.6.3.Information on exposure of food- producing animals and food and feeding stuffs associated with the intended uses of the active substance | ||
7.6.4.Information on exposure from treated articles including leaching data (either laboratory studies or model data) | ||
8. TOXICOLOGICAL PROFILE FOR HUMAN AND ANIMAL INCLUDING METABOLISM | ||
8.1.Skin irritation or skin corrosionThe assessment of this endpoint shall be carried out according to the sequential testing strategy for dermal irritation and corrosion set out in the Appendix to Test Guideline B.4. Acute Toxicity-Dermal Irritation/Corrosion (Annex B.4. to Regulation (EC) No 440/2008) | ||
8.2.Eye irritationThe assessment of this endpoint shall be carried out according to the sequential testing strategy for eye irritation and corrosion as set down in the Appendix to Test Guideline B.5.Acute Toxicity: Eye Irritation/Corrosion (Annex B.5. to Regulation (EC) No 440/2008) | ||
8.3.Skin sensitisationThe assessment of this endpoint shall comprise the following consecutive steps: 1. an assessment of the available human, animal and alternative data 2. in vivo testing The Murine Local Lymph Node Assay (LLNA) including, where appropriate, the reduced variant of the assay, is the first-choice method for in vivo testing. If another skin sensitisation test is used justification shall be provided | Step 2 does not need to be conducted if:
| |
8.4.Respiratory sensitisation | ADS | |
8.5. Mutagenicity | ||
The assessment of this endpoint shall comprise the following consecutive steps:
| ||
8.5.1.In vitro gene mutation study in bacteria | ||
8.5.2.In vitro cytogenicity study in mammalian cells | ||
8.5.3.In vitro gene mutation study in mammalian cells | ||
8.6.In vivo genotoxicity studyThe assessment of this endpoint shall comprise the following consecutive steps:
| ADS | The study/ies do(es) not generally need to be conducted if:
|
8.7.Acute toxicityIn addition to the oral route of administration (8.7.1), for substances other than gases, the information mentioned under 8.7.2 to 8.7.3 shall be provided for at least one other route of administration
| The study/ies do(es) not generally need to be conducted if:
| |
8.7.1.By oral routeThe Acute Toxic Class Method is the preferred method for the determination of this endpoint | The study need not be conducted if:
| |
8.7.2.By inhalationTesting by the inhalation route is appropriate if exposure of humans via inhalation is likely taking into account:
| ||
8.7.3.By dermal routeTesting by the dermal route is necessary only if:
| ||
8.8. Toxicokinetics and metabolism studies in mammals | ||
The toxicokinetics and metabolism studies should provide basic data about the rate and extent of absorption, the tissue distribution and the relevant metabolic pathway including the degree of metabolism, the routes and rate of excretion and the relevant metabolites | ||
8.8.1.Further toxicokinetic and metabolism studies in mammalsAdditional studies might be required based on the outcome of the toxicokinetic and metabolism study conducted in rat. These further studies shall be required if:
Where it is considered appropriate to obtain information on dermal absorption, the assessment of this endpoint shall proceed using a tiered approach for assessment of dermal absorption | ADS | |
8.9.Repeated dose toxicityIn general, only one route of administration is necessary and the oral route is the preferred route. However, in some cases it may be necessary to evaluate more than one route of exposure. For the evaluation of the safety of consumers in relation to active substances that may end up in food or feed, it is necessary to conduct toxicity studies by the oral route Testing by the dermal route shall be considered if:
Testing by the inhalation route shall be considered if:
| The repeated dose toxicity study (28 or 90 days) does not need to be conducted if:
In order to reduce testing carried out on vertebrates and in particular the need for free-standing single-endpoint studies, the design of the repeated dose toxicity studies shall take account of the possibility to explore several endpoints within the framework of one study | |
8.9.1.Short-term repeated dose toxicity study (28 days), preferred species is rat | The short-term toxicity study (28 days) does not need to be conducted if: (i) a reliable sub-chronic (90 day) study is available, provided that the most appropriate species, dosage, solvent and route of administration were used, (ii) the frequency and duration of human exposure indicates that a longer term study is appropriate and one of the following conditions is met:
| |
8.9.2.Sub-chronic repeated dose toxicity study (90 days), preferred species is rat | The sub-chronic toxicity study (90 days) does not need to be conducted if:
| |
8.9.3.Long-term repeated dose toxicity (≥ 12 months) | The long-term toxicity study (≥ 12 months) does not need to be conducted if:
| |
8.9.4.Further repeat dose studiesFurther repeat dose studies including testing on a second species (non-rodent), studies of longer duration or through a different route of administration shall be undertaken in case of:
| ADS | |
8.10.Reproductive toxicityFor evaluation of consumer safety of active substances that may end up in food or feed, it is necessary to conduct toxicity studies by the oral route | The studies need not be conducted if:
| |
8.10.1.Pre-natal developmental toxicity study, preferred species is rabbit; oral route of administration is the preferred route.The study shall be initially performed on one species | ||
8.10.2.Two-generation reproductive toxicity study, rat, oral route of administration is the preferred route.If another reproductive toxicity test is used justification shall be provided. The extended one-generation reproductive toxicity study adopted at OECD level shall be considered as an alternative approach to the multi-generation study | ||
8.10.3.Further pre-natal developmental toxicity study. A decision on the need to perform additional studies on a second species or mechanistic studies should be based on the outcome of the first test (8.10.1) and all other relevant available data (in particular rodent reprotox studies). Preferred species is rat, oral route of administration | ADS | |
8.11.CarcinogenicitySee 8.11.1 for new study requirements | A carcinogenicity study does not need to be conducted if:
| |
8.11.1.Combined carcinogenicity study and long-term repeated dose toxicityRat, oral route of administration is the preferred route. If an alternative route is proposed a justification must be provided. For evaluation of consumer safety of active substances that may end up in food or feed, it is necessary to conduct toxicity studies by the oral route | ||
8.11.2.Carcinogenicity testing in a second species
| ||
8.12. Relevant health data, observations and treatments | ||
Justification should be provided if data is not available | ||
8.12.1.Medical surveillance data on manufacturing plant personnel | ||
8.12.2.Direct observation, e.g. clinical cases, poisoning incidents | ||
8.12.3.Health records, both from industry and any other available sources | ||
8.12.4.Epidemiological studies on the general population | ||
8.12.5.Diagnosis of poisoning including specific signs of poisoning and clinical tests | ||
8.12.6.Sensitisation/allergenicity observations | ||
8.12.7.Specific treatment in case of an accident or poisoning: first aid measures, antidotes and medical treatment, if known | ||
8.12.8.Prognosis following poisoning | ||
8.13.Additional studiesAdditional data which may be required depending on the characteristics and intended use of the active substance Other available data: Available data from emerging methods and models, including toxicity pathway-based risk assessment, in vitro and ‘omic’ (genomic, proteomic, metabolomic, etc.) studies, systems biology, computational toxicology, bioinformatics, and high-throughput screening shall be submitted in parallel | ADS | |
8.13.1.Phototoxicity | ADS | |
8.13.2.Neurotoxicity including developmental neurotoxicity
If the active substance is an organophosphorus compound or if there is any evidence e.g. knowledge of the mechanism of action or from repeat dose studies that the active substance may have neurotoxic or developmental neurotoxic properties then additional information or specific studies will be required. For evaluation of consumer safety of active substances that may end up in food or feed, it is necessary to conduct toxicity studies by the oral route | ADS | |
8.13.3.Endocrine disruptionIf there is any evidence from in vitro, repeat dose or reproduction toxicity studies, that the active substance may have endocrine disrupting properties then additional information or specific studies shall be required to:
For evaluation of consumer safety of active substances that may end up in food or feed, it is necessary to conduct toxicity studies by the oral route | ADS | |
8.13.4.Immunotoxicity including developmental immunotoxicityIf there is any evidence, from skin sensitisation, repeat dose or reproduction toxicity studies, that the active substance may have immunotoxic properties then additional information or specific studies shall be required to:
For evaluation of consumer safety of active substances that may end up in food or feed, it is necessary to conduct toxicity studies by the oral route | ADS | |
8.13.5.Mechanistic data — any studies necessary to clarify effects reported in toxicity studies | ADS | |
8.14.Studies related to the exposure of humans to the active substance | ADS | |
8.15.Toxic effects on livestock and pets | ADS | |
8.16.Food and feeding stuffs studies including for food-producing animals and their products (milk, eggs and honey)Additional information related to the exposure of humans to the active substance contained in biocidal products | ADS | |
8.16.1.Proposed acceptable residue levels i.e. maximum residue limits (MRL) and the justification of their acceptability | ADS | |
8.16.2.Behaviour of the residue of the active substance on the treated or contaminated food or feeding stuffs including the kinetics of disappearanceResidue definitions should be provided where relevant. It is also important to compare residues found in toxicity studies with residues formed in food-producing animals and their products, as well as food and feed | ADS | |
8.16.3.Overall material balance for the active substanceSufficient residue data from supervised trials on food- producing animals and their products, as well as food and feed, to demonstrate that residues likely to arise from the proposed use would not be of concern for human or animal health | ADS | |
8.16.4.Estimation of potential or actual exposure of humans to the active substance and residues through diet and other means | ADS | |
8.16.5.If residues of the active substance occur in or on feeding stuffs for a significant period of time or are found in food of animal origin after treatment on or around food-producing animals (e.g. direct treatment on animals or indirect treatment of animal houses or surroundings) then feeding and metabolism studies in livestock shall be required to permit evaluation of residues in food of animal origin | ADS | |
8.16.6.Effects of industrial processing and/or domestic preparation on the nature and magnitude of residues of the active substance | ADS | |
8.16.7.Any other available information that is relevantIt may be appropriate to include information on migration into food, especially in the case of treatment of food contact materials | ADS | |
8.16.8.Summary and evaluation of data submitted under 8.16.1 to 8.16.8It is important to establish whether the metabolites found in food (from animals or plants) are the same as those tested in toxicity studies. Otherwise values for risk assessment (e.g. ADI) are not valid for the residues found | ADS | |
8.17.If the active substance is to be used in products for action against plants including algae then tests shall be required to assess toxic effects of metabolites from treated plants, if any, where different from those identified in animals | ADS | |
8.18.Summary of mammalian toxicologyProvide overall evaluation and conclusion with regard to all toxicological data and any other information concerning the active substances including NOAEL | ||
9. ECOTOXICOLOGICAL STUDIES | ||
9.1. Toxicity to Aquatic Organisms | ||
9.1.1.Short-term toxicity testing on fishWhen short-term fish toxicity data is required the threshold approach (tiered strategy) should be applied | The study does not need to be conducted if:
| |
9.1.2. Short-term toxicity testing on aquatic invertebrates | ||
9.1.2.1.Daphnia magna | ||
9.1.2.2.Other species | ADS | |
9.1.3. Growth inhibition study on algae | ||
9.1.3.1.Effects on growth rate of green algae | ||
9.1.3.2.Effects on growth rate of cyanobacteria or diatoms | ||
9.1.4.Bioconcentration | The experimental determination may not need to be carried out if:
| |
9.1.4.1.Estimation methods | ||
9.1.4.2.Experimental determination | ||
9.1.5.Inhibition of microbial activityThe study may be replaced by a nitrification inhibition test if available data show that the substance is likely to be an inhibitor of microbial growth or function, in particular nitrifying bacteria | ||
9.1.6.Further Toxicity Studies on Aquatic OrganismsIf the results of the ecotoxicological studies, studies on fate and behaviour and/or the intended use(s) of the active substance indicate a risk for the aquatic environment, or if long-term exposure is expected, then one or more of the tests described in this Section shall be conducted | ADS | |
9.1.6.1.Long term toxicity testing on Fish(a) Fish Early Life Stage (FELS) Test (b) Fish short term toxicity test on embryo and sack fry stages (c) Fish juvenile growth test (d) Fish full life cycle test | ADS | |
9.1.6.2.Long term toxicity testing on invertebrates(a) Daphnia growth and reproduction study (b) Other species reproduction and growth (e.g. Mysid) (c) Other species development and emergence (e.g. Chironomus) | ADS | |
9.1.7.Bioaccumulation in an appropriate aquatic species | ADS | |
9.1.8.Effects on any other specific, non-target organisms (flora and fauna) believed to be at risk | ADS | |
9.1.9.Studies on sediment- dwelling organisms | ADS | |
9.1.10.Effects on aquatic macrophytes | ADS | |
9.2.Terrestrial toxicity, initial tests | ADS | |
9.2.1.Effects on soil micro-organisms | ||
9.2.2.Effects on earthworms or other soil- dwelling non-target invertebrates | ||
9.2.3.Acute toxicity to plants | ||
9.3.Terrestrial tests, long term | ADS | |
9.3.1.Reproduction study with earthworms or other soil-dwelling non-target invertebrates | ||
9.4.Effects on birds | ADS | For endpoint 9.4.3 the study does not need to be conducted if:
|
9.4.1.Acute oral toxicity | ||
9.4.2.Short-term toxicity — eight-day dietary study in at least one species (other than chickens, ducks and geese) | ||
9.4.3.Effects on reproduction | ||
9.5.Effects on arthropods | ADS | |
9.5.1.Effects on honeybees | ||
9.5.2.Other non-target terrestrial arthropods, e.g. predators | ||
9.6.Bioconcentration, terrestrial | ADS | |
9.7.Bioaccumulation, terrestrial | ADS | |
9.8.Effects on other non-target, non-aquatic organisms | ADS | |
9.9.Effects on mammals | ADS | Data are derived from the mammalian toxicological assessment. The most sensitive relevant mammalian long-term toxicological endpoint (NOAEL) expressed as mg test compound/kg bw/day shall be reported |
9.9.1.Acute oral toxicity | ||
9.9.2.Short term toxicity | ||
9.9.3.Long term toxicity | ||
9.9.4.Effects on reproduction | ||
9.10.Identification of endocrine activity | ADS | |
10. ENVIRONMENTAL FATE AND BEHAVIOUR | ||
10.1. Fate and behaviour in water and sediment | ||
10.1.1. Degradation, initial studies | ||
If the assessment performed indicates the need to investigate further the degradation of the substance and its degradation products or the active substance has an overall low or absent abiotic degradation, then the tests described in 10.1.3 and 10.3.2 and where appropriate — in 10.4 shall be required. The choice of the appropriate test(s) depends on the results of the initial assessment performed | ||
10.1.1.1.Abiotic | ||
(a)Hydrolysis as a function of pH and identification of breakdown products
| ||
(b)Phototransformation in water, including identification of transformation products | ||
10.1.1.2.Biotic | ||
(a)Ready biodegradability | ||
(b)Inherent biodegradability (where appropriate) | ||
10.1.2.Adsorption/desorption | ||
10.1.3. Rate and route of degradation including identification of metabolites and degradation products | ||
10.1.3.1.Biological sewage treatment | ||
(a)Aerobic biodegradation | ADS | |
(b)Anaerobic biodegradation | ADS | |
(c)STP simulation test | ADS | |
10.1.3.2.Biodegradation in freshwater | ||
(a)Aerobic aquatic degradation study | ADS | |
(b)Water/sediment degradation test | ADS | |
10.1.3.3.Biodegradation in sea water | ADS | |
10.1.3.4.Biodegradation during manure storage | ADS | |
10.1.4.Adsorption and desorption in water/aquatic sediment systems and, where relevant, adsorption and desorption of metabolites and degradation products | ADS | |
10.1.5.Field study on accumulation in sediment | ADS | |
10.1.6.Inorganic substances: information on fate and behaviour in water | ADS | |
10.2.Fate and behaviour in soil | ADS | |
10.2.1.Laboratory study on rate and route of degradation including identification of the processes involved and identification of any metabolites and degradation products in one soil type (unless pH dependent route) under appropriate conditionsLaboratory studies on rate of degradation in three additional soil types | ADS | |
10.2.2.Field studies, two soil types | ADS | |
10.2.3.Soil accumulation studies | ADS | |
10.2.4.Adsorption and desorption in at least three soil types and, where relevant, adsorption and desorption of metabolites and degradation products | ADS | |
10.2.5.Further studies on sorption | ||
10.2.6.Mobility in at least three soil types and where relevant mobility of metabolites and degradation products | ADS | |
10.2.6.1.Column leaching studies | ||
10.2.6.2.Lysimeter studies | ||
10.2.6.3.Field leaching studies | ||
10.2.7.Extent and nature of bound residuesThe determination and characteristics of bound residues is recommended to be combined with a soil simulation study | ADS | |
10.2.8.Other soil degradation studies | ADS | |
10.2.9.Inorganic substances: information on fate and behaviour in soil | ||
10.3. Fate and behaviour in air | ||
10.3.1.Phototransformation in air (estimation method)Identification of transformation products | ||
10.3.2.Fate and behaviour in air, further studies | ADS | |
10.4.Additional studies on fate and behaviour in the environment | ADS | |
10.5.Definition of the residue | ADS | |
10.5.1.Definition of the residue for risk assessment | ||
10.5.2.Definition of the residue for monitoring | ||
10.6.Monitoring data | ADS | |
10.6.1.Identification of all degradation products (> 10 %) must be included in the studies on degradation in soil, water and sediments | ||
11. MEASURES NECESSARY TO PROTECT HUMANS, ANIMALS AND THE ENVIRONMENT | ||
11.1.Recommended methods and precautions concerning handling, use, storage, transport or fire | ||
11.2.In case of fire, nature of reaction products, combustion gases etc. | ||
11.3.Emergency measures in case of accident | ||
11.4.Possibility of destruction or decontamination following release in or on the following:(a) air (b) water, including drinking water (c) soil | ||
11.5.Procedures for waste management of the active substance for industry or professional users | ||
11.6.Possibility of reuse or recycling | ||
11.7.Possibility of neutralisation of effects | ||
11.8.Conditions for controlled discharge including leachate qualities on disposal | ||
11.9.Conditions for controlled incineration | ||
11.10.Identification of any substances falling within the scope of List I or List II of the Annex to Council Directive 80/68/EEC of 17 December 1979 on the protection of groundwater against pollution caused by certain dangerous substancesc, of Annexes I and II to Directive 2006/118/EC of the European Parliament and of the Council of 12 December 2006 on the protection of groundwater against pollution and deteriorationd, of Annex I to Directive 2008/105/EC of the European Parliament and of the Council of 16 December 2008 on environmental quality standards in the field of water policye, of Part B of Annex I to Directive 98/83/EC or Annexes VIII and X to Directive 2000/60/EC | ||
12. CLASSIFICATION, LABELLING AND PACKAGING | ||
12.1.State any existing classification and labelling | ||
12.2. The hazard classification of the substance resulting from the application of Regulation (EC) No 1272/2008 | ||
In addition, for each entry, the reasons why no classification is given for an endpoint should be provided | ||
12.2.1.Hazard classification | ||
12.2.2.Hazard pictogram | ||
12.2.3.Signal word | ||
12.2.4.Hazard statements | ||
12.2.5.Precautionary statements including prevention, response, storage and disposal | ||
12.3.Specific concentration limits, where applicable, resulting from the application of Regulation (EC) No 1272/2008 | ||
13.SUMMARY AND EVALUATIONThe key information identified from the endpoints in each subsection (2-12) is summarised, evaluated and a draft risk assessment is performed |
Information required to support the approval of an active substance is listed in the table below.
Conditions for not requiring a specific test that are set out in the appropriate test methods in Regulation (EC) No 440/2008 that are not repeated in column 3, also apply.
The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.
The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.
For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: